Technology Bundle ID: TAB-2703

Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi

Request More Info
Licensing Contact:
Primary Inventors: 
Christine Morrison (CDC)
Cheryl Elie (CDC), Errol Reiss (CDC), Timonthy Lott (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 

This invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of the Candida fungi species C. haemulonii, C. kefyr, C. lambica, C. lusitaniae, C. norvegensis, C. norvegica, C. rugosa, C. utilis, C. viswanathii, C. zeylanoides, C. dubliniensis, and C. pelliculosa within biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are specific for each species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients.

  • Directing antifungal drug therapy for improved patient outcomes
  • Detection, discrimination of Candida species from biological samples
  • Addressing secondary infections of immunosuppressed individuals
  • Easily adapted for use in kits
  • High-throughput capable
  • Rapid and cost-effective


PCT Application PCT/US1998/015840
Filed on 1998-07-30
US Pat 6,242,178

Issued 2001-06-05


Shin JH, et al.
PMID 9854084


Dec 23, 2013

Data Source: